Biocon Biologics Limited, a global biosimilars company based in Bengaluru, India, has announced a new partnership with the National Cancer Society of Malaysia (NCSM). The goal is to expand access to affordable and high-quality cancer medicines in Malaysia. This initiative, called the Patient Assistance Program (PAP), will help underserved cancer patients receive the treatment they need without financial burden.
As part of this collaboration, Biocon Biologics will supply biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim, and Bevacizumab. These are important drugs used in cancer treatment. The NCSM will handle the enrolment of patients and manage the distribution of medicines through its healthcare services.
The program will start with the distribution of Trastuzumab, a drug used to treat breast cancer, especially for patients who are facing delays in their treatment due to budget issues.
This collaboration was formalised with a Memorandum of Understanding (MoU) signed at the National Cancer Congress Malaysia 2025. The signing was attended by Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, and Dato' Dr. Saunthari Somasundaram, President of NCSM. Malaysia's Health Minister, Datuk Seri Dr Dzulkefly Ahmad, was also present at the event. This partnership highlights a strong commitment to delivering patient-focused healthcare solutions in the country.
Biocon Biologics has already made a significant contribution to diabetes care in Malaysia, serving over 345,000 patients. With this new initiative, the company is expanding its reach into oncology to help cancer patients who lack access to advanced treatment. The partnership with NCSM strengthens this effort, combining Biocon’s medical expertise with NCSM’s trusted reputation and extensive network in local communities.
NCSM is Malaysia’s first not-for-profit cancer organisation, offering services such as education, medical care, and emotional support to cancer patients. It is well-known in Malaysia for its transparency, fairness, and commitment to the community.
Biocon Biologics Ltd. (BBL) is a subsidiary of Biocon Limited and is one of the world’s leading biosimilar companies. It operates across more than 120 countries and aims to make biological treatments affordable and accessible. The company combines cutting-edge science, digital innovation, and efficient global manufacturing to bring high-quality medicines to patients worldwide.
Founded in 2004, Biocon Limited is a publicly listed, innovation-driven global biopharmaceutical company. It focuses on affordable access to complex therapies for chronic diseases like diabetes, cancer, and autoimmune disorders. Biocon has developed and commercialized novel biologics, biosimilars, and small molecule APIs across several international markets, including India, the U.S., and Europe.
As of June 24, 2025, Biocon share price is trading at ₹348.50, down 1.05% from the previous close. The stock opened at ₹350.00 and touched a high of ₹351.50 and a low of ₹346.75 during the session. The quarterly dividend amount is ₹0.12 per share.
The partnership between Biocon Biologics and the National Cancer Society of Malaysia is a powerful step toward improving cancer treatment accessibility in the country. By combining Biocon’s global experience in biosimilars with NCSM’s local reach and credibility, this program can provide timely, affordable, and high-quality care to thousands of patients.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jun 24, 2025, 9:20 AM IST
Kusum Kumari
Kusum Kumari is a Content Writer with 4 years of experience in simplifying financial market concepts. Currently crafting insightful content at Angel One, She specialise in breaking down complex topics into easy-to-understand pieces, blending expertise in market fundamentals and technical analysis.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
